2022年11月3日 · 结果发现，粒细胞-巨噬细胞集落刺激因子（GM-CSF）分泌的异源基因PDAC疫苗（GVAX）可以在一次接种后仅2周诱导PDAC中形成淋巴聚集物（LA）。 此外，程序性死亡配体1（PD-L1）的表达在这些淋巴聚集物内的肿瘤上皮细胞和髓系细胞上都被诱导，这表明疫苗治疗可能会启动PDAC对ICI的反应。 这些研究表明，有可能将PDAC转化为免疫反应性肿瘤。 然而，临床反应率仍然很低。 因此，当前的挑战是在复杂的PDAC TME中识别额外的免疫调节信号， …

2018年10月31日 · Our data reveal PCs innately express PD-1 and activate druggable oncogenic pathways supporting PDAC growth. Strategies directly targeting PC with novel ICI regimens may work with adaptive...

3 天之前 · Patients with advanced pancreatic ductal adenocarcinoma (PDAC) generally face a poor prognosis and limited therapeutic options. This study aims to evaluate the clinical efficacy of combining PD- 1 ...

Immunotherapy targeting programmed cell death-1 (PD-1) has considerably improved the prognosis of patients with advanced cancers; however, its efficacy in the treatment of pancreatic ductal adenocarcinoma (PDAC) is unfavourable. To address the issue of PDAC immunotherapy, we investigated the express …

PD-1 immune checkpoint molecule is one of the most popular markers of T lymphocytes in the tumor microenvironment. PD-1 single immunotherapy to PDAC may show no good results, but a combination with other immunotherapies, chemotherapies or radiotherapies may obtain a …

2021年5月28日 · Recently, maintenance therapy on pancreatic cancer was widely investigated in clinical trials. The present study explored the camrelizumab (anti-PD-1 antibody) combined with AG as the first-line treatment, and camrelizumab as maintenance therapy for metastatic PDAC (mPDAC) among Chinese patients.

2019年3月4日 · This article aims to deeply understand the value of PD-1 immune checkpoint inhibitor in pancreatic cancer and validly provide the evidence for treatment by means of performing a systematic review on the current status in the fields of the mechanism and application of anti-PD-1 in pancreatic cancer, associations with surgery, PD-1-related side ...

2022年6月21日 · We recently demonstrated that immune checkpoint PD-1 was endogenously expressed in pancreatic ductal adenocarcinoma (PDAC) cells. Our data indicated that PD-1 proteins are not exclusive to immune cells and have unrecognized signal transduction cascades intrinsic to cancer cells.

2023年10月6日 · PD1-IL2v+RT can inhibit the progression of PDAC by enhancing the activation, proliferation, invasion and migration of CD8 + T cells and NK cells in blood, lymph nodes and...

2024年9月4日 · Pancreatic ductal adenocarcinoma (PDAC) has a survival rate of 12%, and multiple clinical trials testing anti-PD-1 therapies against PDAC have failed, suggesting a need for a novel therapeutic strategy. In this study, we evaluated the potential of milbemycin oxime (MBO), an antiparasitic compound, as an immunomodulatory agent in PDAC.